BridgeBio Pharma Presents Additional Data and Analyses From Its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis
BridgeBio Pharma Presents Additional Data and Analyses From Its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis
BridgeBio Pharma提供了其轉甲狀腺素澱粉樣心肌病的3期Atribute-CM研究的更多數據和分析，包括在預先規定的靈敏度分析中阿科拉米德治療顯著降低了全因死亡率
BridgeBio Pharma Presents Additional Data and Analyses From Its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis
BridgeBio Pharma提供了其轉甲狀腺素澱粉樣心肌病的3期Atribute-CM研究的更多數據和分析，包括在預先規定的靈敏度分析中阿科拉米德治療顯著降低了全因死亡率
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。